Viking Therap

Viking Therapeutics opened lower in regular trading and continued to decline, last trading at $31.69 as of 9:34 ET, down approximately 5.2% from the prior close of $33.43. The intraday low reached $31.11, driven by ongoing R&D expenditure expansion despite Q2 earnings slightly beating estimates (EPS -$1.10 vs. consensus -$1.25). Net loss widened to $158.3 million, up 247% YoY, and operating loss widened to $164.1 million, up 196% YoY, with no revenue generated. In terms of price positioning, the stock is now 26.6% below its 52-week high of $43.15 and trades below both the 20-day MA ($37.06) and 60-day MA ($33.46), indicating a weak technical picture. However, post-market trading saw the stock recover to $33.44, near the prior close, suggesting some investors reassessed the value of VK2735's potential in obesity maintenance therapy after the earnings release.

Viking Therapeutics closed the regular session down 5.05% at $35.90, driven by a reversal from a pre-market high of $39.00 amid persistent earnings losses. The company reported a Q1 2026 net loss of $158.3 million (widening 247% YoY) and EPS of -$1.37, reflecting high R&D costs. The stock now sits 16.8% below its 52-week high of $43.15 but remains above the 60-day moving average of $32.96, indicating a still-healthy intermediate trend. A post-market bounce to $37.96 offered some relief, though total volume of 1.08 million shares was modest, and investors remain cautious regarding the obesity pipeline's early-stage data.

Viking Therapeutics opened sharply lower in regular trading, reaching $39.00 as of 09:40 ET, down 5.2% from the prior close of $41.14, with 101,830 shares traded. The intraday low touched $39.00, while the full-day range spanned $39.00-$41.60, with a pre-market high of $41.60 before the sell-off. The decline was driven by ongoing digestion of Q1 2026 results: net loss widened to $158.3 million (YoY -246.98%), EPS of -$1.37 (YoY -236.48%), and no revenue recorded. The stock at $39.00 sits below its 20-day MA of $35.59 and 60-day MA of $32.83, and is 9.62% off its 52-week high of $43.15, though it remains up 10.11% year-to-date, reflecting long-term positioning around the VK2809 NASH program.

Viking Therapeutics opened higher but closed sharply lower, retreating from an intraday high of $42.280 to end at $39.970, down 5.13%. The downward move was driven by intensifying competitive pressure: the UK approved Novo Nordisk's oral weight-loss pill and several smaller players advanced their obesity pipelines, raising concerns about VKTX's first-mover advantage. Despite initiating a Phase 1 trial for VK3019, a novel amylin receptor agonist, and analysts reiterating a $102 price target, the stock remains near its 52-week high ($43.15), 7.37% below that peak, with a YTD gain of 12.85%. The stock closed above its 20-day MA ($34.432) and 60-day MA ($32.670). However, it edged down 0.18% to $39.900 in after-hours trading, suggesting lingering near-term weakness.

Viking Therapeutics surged 5.05% to $40.665 during regular trading as the company initiated a Phase 1 trial of VK3019, a novel amylin receptor agonist for obesity, following FDA clearance of its IND application. The stock staged a low-to-high rally from $38.87 to an intraday high of $40.665. Despite Q1 net loss widening 247% YoY to $158.3 million with no revenue, the market focused on its obesity pipeline, including VK2735, with analysts reiterating Buy ratings and a $102 price target. The stock now trades above its MA20 ($33.82) and MA60 ($32.55), with YTD gains of 14.81%, and sits just 5.76% below its 52-week high of $43.15. However, after-hours trading saw the price retreat to $38.66, suggesting short-term profit-taking.